Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow (2016 - 2025)

Lineage Cell Therapeutics' Free Cash Flow history spans 16 years, with the latest figure at -$5.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 23.52% year-over-year to -$5.3 million; the TTM value through Dec 2025 reached -$19.4 million, up 17.82%, while the annual FY2025 figure was -$19.4 million, 17.82% up from the prior year.
  • Free Cash Flow reached -$5.3 million in Q4 2025 per LCTX's latest filing, down from -$3.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $21.9 million in Q1 2022 to a low of -$11.4 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$5.7 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: skyrocketed 393.99% in 2022, then tumbled 152.29% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$6.0 million in 2021, then plummeted by 31.28% to -$7.9 million in 2022, then grew by 22.68% to -$6.1 million in 2023, then dropped by 12.93% to -$6.9 million in 2024, then rose by 23.52% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Free Cash Flow are -$5.3 million (Q4 2025), -$3.6 million (Q3 2025), and -$5.6 million (Q2 2025).